RICERCA ITALIANA     

Programmi di ricerca simili:

• 1 - Progettazione e sintesi di ligandi recettoriali/enzimatici per lo sviluppo di farmaci ad azione antiischemica/neuroprotettiva e modulatoria del sistema nervoso centrale
• 2 - Agenti Attivi sul Sistema Nervoso Centrale: Moderni Approcci Chimico-Farmaceutici per la Modulazione e Caratterizzazione di Pathways Recettoriali
• 3 - Potenziale terapeutico di nuovi ligandi per il recettore di nocicettina/orfanina FQ
• 4 - Il sistema nocicettina/OFQ-recettore NOP: studi di base e clinici
• 5 - Il sistema neuropeptide S - recettore NPSR: identificazione di nuovi ligandi e studio delle attivita' biologiche in vitro ed in vivo
• 6 - Identificazione, espressione funzionale e caratterizzazione fisiopatologica di nuovi recettori purinici.
• 7 - SINTESI E VALUTAZIONE DI NUOVI LIGANDI PER IL RECETTORE BENZODIAZEPINICO PERIFERICO UTILI PER IL CHIARIMENTO DEL SUO RUOLO FISIO-FARMACOLOGICO E DIAGNOSTICO
• 8 - AGENTI ATTIVI SUL SNC: PROGETTAZIONE E SINTESI DI MODULATORI DI PATHWAYS BIOCHIMICI IMPLICATI IN DISORDINI NEURODEGENERATIVI E PSICHIATRICI.
• 9 - Nuovi ligandi e modulatori per la caratterizzazione dei neurorecettori e per il trattamento delle relative disfunzioni
• 10 - SINTESI E CARATTERIZZAZIONE FARMACOLOGICA DI NUOVE MOLECOLE SELETTIVE PER IL RECETTORE BENZODIAZEPINICO PERIFERICO UTILI PER LA MODULAZIONE DELLA NEUROSTEROIDOGENESI, PER LA DIAGNOSI DI MALATTIE NEURODEGENERATIVE E PER IL DIREZIONAMENTO DI FARMACI ANTITUMORALI

Classificazione scientifico-disciplinare

• Area scientifico disciplinare: Scienze chimiche
  • CHIMICA FARMACEUTICA

Classificazione brevettuale

• CHEMISTRY; METALLURGY
  • ORGANIC CHEMISTRY (such compounds as the oxides, sulfides, or oxysulfides of carbon, cyanogen, phosgene, hydrocyanic acid or salts thereof C01; products obtained from layered base-exchange silicates by ion-exchange with organic compounds such as ammonium, phosphonium or sulfonium compounds or by intercalation of organic compounds C01B33/44; macromolecular compounds C08; dyes C09; fermentation products C12; fermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture C12P; production of organic compounds by electrolysis or electrophoresis C25B3/00, C25B7/00)
    • HETEROCYCLIC COMPOUNDS
    • SUGARS; DERIVATIVES THEREOF (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C121/36; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; sugar and starch industry C13)

Classificazione geografica

• Regione: Sicilia

Bibliografia

Delta opioid peptide (D-Ala,D-Leu 5)-enkephalin: linking hibernation and neuroprotection. T-P Su et al - Frontiers in Bioscience (2004), 9(suppl.), 3392-3398
The effects of the delta-opioid agonist SNC80 on hind-limb motor function and neuronal injury after spinal cord ischemia in rats, T Horiuchi et al, Anesthesia & Analgesia (2004), 99(1), 235-240
Prolonged opportunity for ischemic neuroprotection with selective kappa-opioid receptor agonist in rats, T-Y Chen et al, Stroke (2004), 35)(5), 1180-1185
The sigma receptor ligand (+)-pentazocine prevents apoptotic retinal ganglionic cell death induced in vitro by homocysteine and glutamate, PM Martin et al, Molecular Brain Res (2004), 123(1-2), 66-75
Kappa-opioid receptor selectivity for ischemic neuroprotection with BRL 52537 in rats, Z Zhang et al, Anesthesia & Analgesia (2003, 97(6), 1776-1783
Homodimerization of the beta2-adrenergic receptor as a prerequisite for cell surface targeting, Salahpour A. Angers S. Mercier JF. Lagace M. Marullo S. Bouvier M. J. Biol. Chem.. 279(32):33390-7, 2004
Dimer dissociation is essential for interleukin-8 (IL-8) binding to CXCR1 receptor. Fernando H. Chin C. Rosgen J. Rajarathnam K., J. Biol. Chem. 279:36175-36178 (2004
Neuroprotective kappa-opioid receptor agonist BRL 52537 attenuates ischemia-evoked Nitric oxide production in vivo in rats, T Goyagi et al, Stroke (2003), 34(6), 1533-1538
Cross-talk of opioid peptide receptor and beta-adrenergic receptor signalling in the heart. Pepe S. van den Brink OW. Lakatta EG. Xiao RP. Cardiovasc. Res. 63: 414-422, 2004
Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking Grant M. Collier B. Kumar U. J. Biol. Chem. 279: 36179-36183 (2004)
A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia, Gomes I. Gupta A. Filipovska J. Szeto HH. Pintar JE. Devi LA. Proc. Natl Acad. Sci. USA. 101: 5135-5139 (2004
A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers, Bhushan RG. Sharma SK. Xie Z. Daniels DJ. Portoghese PS.J. Med. Chem. 47: 2969-2972 (2004)]
Xiang J.-N., Lee, J.C. Pharmacology of Cannabinoid Receptors Agonista and Antagonista. Annual Reports in Medicinal Chemistry, Chapt 20, volume 34, Academic Press 1999.
Piomelli, D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci. 2003, 4, 873.
Di Marzo, V. et al The endocannabinoid system and its therapeutic exploitation. Nat. Rev. Drug Disc. 2004, 3, 771.
Corchero, J. et al Cannabinoid/opioid crosstalk in the Central Nervous System, Crit. Rev. Neurobiol., 2004, 16, 159-72.
Valverde, O. et al Involvement of the endogenous opioid system in cannabinoid response. Current Med. Chem. CNS agents, 2004, 4, 189-93.
Freund, T. et al Role of endogenous cannabinoids i synaptic signaling. Physiological Reviews, 2003, 83, 1017-1066.
Kathuria, S. et al Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. 2003, 9, 76.
Piomelli, D. et al Preparation and use of carbamates for modulation of anxiety through blockade of anandamide hydrolysis PCT Int. Appl. WO 033422, 2004.
Gaetani, S. et al Anandamide hydrolysis: a new target for anxiety drugs? Trends Mol. Med. 2003, 9, 474.
Tarzia, G. et al Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J. Med. Chem. 2003, 46, 2352.
Mor, M. et al Cyclohexylcarbamic acid 3’- or 4’-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships and molecular modelling studies. J. Med. Chem. 2004, 47, 4998.
Panikashvili, D. et al An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001, 413, 527.
Rivara S. et al J. Med. Chem. 2003, 46, 1429-1439.
Lucini V. et al J. Med. Chem. 2004, 47, in press.
Dubocovich M.L. et al Arch. Pharmacol. 1997, 355, 365-375.
Rivara S. et al J. Med. Chem. Accepted for publication
Bräuner-Osborne, H. et al Ligands for glutamate receptors: Design and therapeutic prospects. J. Med. Chem. 2000, 43, 2609-2645
Jonas, P.; Monyer, H. Eds. Handbook of Experimental Pharmacology, Ionotropic Glutamate Receptors in the CNS, Springer-Verlag: Berlin, vol. 141, 1999
Knopfel, T. et al Metabotropic glutamate receptors: novel targets for drug development. J. Med. Chem. 1995, 38, 1417-1426
Lees, G.J. Pharmacology of AMPA-kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs 2000, 59, 33-78
5Jonas, P.; Monyer, H. Eds. Handbook of Experimental Pharmacology, Ionotropic Glutamate Receptors in the CNS, Springer-Verlag: Berlin, vol. 141, 1999
Conn, P.J. et al Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237
Monaghan, D.T. et al The Ionotropic Glutamate Receptors. Humana Press, Totowa, NJ, 1997
Jonas, P., Monyer, H., Handbook of Experimental Pharmacology, Ionotropic Glutamate Receptors in the CNS vol. 141. Spinger-Verlag, Berlin, 1999
Brauner-Osborne, H. et al Ligands for glutamate receptors: design and therapeutic prospects. J. Med. Chem. 2000, 43, 2609-2645
Nakanishi, S. Molecular diversity of glutamate receptors and implications for brain function. Science 1992, 258, 597-603
Pin, J. P. et al The metabotropic glutamate receptors: structure and functions. J. Neurochem. 1992, 58, 1184-1186
Schoepp, DD et al Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol. Sci. 1993, 14,13-20
Bockaert, J. et al Metabotropic glutamate receptors: an original family of G protein-coupled receptors. Fandam. Clin. Pharmacol. 1993, 7, 473-485
Hollmann, M. et al Cloned glutamate receptors. Annu. Rev. Neurosci. 1994, 17, 31-108
Chittajallu,R. et al Kainate receptors: subunit, synaptic localization and function. Trends Pharmacol. Sci. 1999, 20, 26-35
Fletcher, EJ et al New developments in the molecular pharmacology of a-amino-3-hydroxy-4-isoxazole propionate and kainate receptors. Phamocol. Ther. 1996, 70, 65-89
Bigge, CF et al Curr. Pharm. Des. 1996, 2, 397-412
Moebius, FF et al Sigma receptors: new family members reveal a role in cholesterol synthesis. Trends Pharmacol. Sci. 1997, 18, 67-70.
Maurice, T et al Neuroactive steroids as endogenous effectors for the sigma1 (1) receptor: pharmacological evidence and therapeutic opportunities. Jpn. J. Pharmacol. 1999, 81, 125-155
Su, TP et al Steroid binding at sigma receptors suggests a link between endocrine, nervous and immune systems. Science 1988, 240, 219-221
Oliver, B et al The 5-HT1A receptor and its ligands: structure and function. Prog. Drug Res. 52, 103, 1999
De Vry, J et al Behavioral Pharmacology of 5-HT1A agonists: animal model of anxiety and depression. In Serotonin1A Receptors in Depression and Anviety; Stahl, S.M. et al. Eds; Raven Press: Nex York, 1992; pp 55-81
Semkova, I et al Neuroprotective effect of 5-HT1A receptor agonist, BAYx3702, demostrated in vitro and in vivo. Eur. J. Pharmacol. 359, 251, 1998
Ramos, AJ et al The 5-HT1A receptor agonist, 8-OH-DPTA, protect neurons and reduced astroglial reaction after ischemic damage caused by cortical devascularization. Brain Research. 1030, 201, 2004
Fletcher, A et al Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100,635 a potent, selective and silent 5-HT1A receptor antagonist. Behav. Brain Res. 73, 337, 1996
B. Bontempi et al Cognitive enhancing properties and tolerability of cholinergicagents in mice: a comparative study of nicotine, donezepil, and SIB-1553A, a subtype-selective ligand for nicotinic acetylcholine receptors. Neuropharmacology 28 (2003) 1235-1246

Parole Chiave

FARMACI PER LE PATOLOGIE DEL SNC; LIGANDI RECETTORIALI; COMPOSTI CHIMICI PER L'ANALISI FARMACOLOGICA; SINTESI E SPERIMENTAZIONE FARMACOLOGICA; DRUG DESIGN